Skip to main content

Lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids Disease Interactions

There are 3 disease interactions with lactobacillus rhamnosus gg / omega-3 polyunsaturated fatty acids.

Moderate

Omega-3 fatty acids (applies to lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids) arrhythmias

Moderate Potential Hazard, Moderate plausibility.

Cases of recurrent atrial fibrillation (AF) or flutter have been reported with the use of omega-3 fatty acids in patients with a symptomatic paroxysmal AF or persistent AF. This condition is more apparent within the first 2 to 3 months after the initiation of therapy. Therapy with these agents should be administered cautiously in patients with cardiac conduction disorders.

References (1)
  1. (2005) "Product Information. Omacor (omega-3 polyunsaturated fatty acids)." Abbott Pharmaceutical
Moderate

Omega-3 fatty acids (applies to lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids) liver disease

Moderate Potential Hazard, Moderate plausibility.

Increases in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels have been observed in patients receiving omega-3 fatty acids. Therapy with omega-3 fatty acid preparations should be administered cautiously in patients with hepatic impairment. Serum liver enzyme levels should be monitored periodically.

References (2)
  1. (2005) "Product Information. Omacor (omega-3 polyunsaturated fatty acids)." Abbott Pharmaceutical
  2. (2021) "Product Information. Lovaza (omega-3 polyunsaturated fatty acids)." Woodward Pharma Services, Rev. 02-2021-00
Moderate

Probiotics (applies to lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids) immunosuppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

Probiotics, especially those containing lactobacillus, should be used with caution in immunosuppressed patients.

References (3)
  1. "Product Information. Culturelle DS (lactobacillus rhamnosus GG)." ConAgra Functional Foods
  2. Salminen MK, Tynkkynen S, Rautelin H, et al. (2002) "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis, 35, p. 1155-60
  3. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK (2005) "Lactobacillus sepsis associated with probiotic therapy." Pediatrics, 115, p. 178-81

Switch to consumer interaction data

Lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids drug interactions

There are 421 drug interactions with lactobacillus rhamnosus gg / omega-3 polyunsaturated fatty acids.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer